

**Australian Securities Exchange  
Companies Announcements Office  
SYDNEY**

**14<sup>th</sup> March 2012**

**SHARE CONSOLIDATION**

Probiomics Limited ("Company" ASX Code:PCC) advised in its announcement dated 3 February, 2012 that the proposed 1:20 share consolidation would occur on 21 March, 2012.

The Company advises that the occurrence of that share consolidation will be slightly delayed and that the Company will be shortly publishing an amended timetable in connection with the steps involved in its intended re-admission to the Official List, including completion of its share consolidation.

**CONTACT**

Mr Ashok Jairath - Chief Financial Officer and Company Secretary

Tel: +612 9844 5422

Email [ashok.jairath@probiomics.com.au](mailto:ashok.jairath@probiomics.com.au)

**About Probiomics Limited**

Probiomics has proprietary ownership of a unique probiotic strain – PCC®

PCC® has been clinically proved to have superior qualities – particularly in promoting systemic immune response.

Probiomics' commercial objective is to earn royalties from licensing PCC® to distribution companies selling products in global markets.

For further information, please go to [www.probiomics.com.au](http://www.probiomics.com.au)